Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEZGWP)

Drug Name
Zabedosertib Drug Info
Synonyms
Zabedosertib; 1931994-81-8; N-[6-(1-hydroxy-1-methyl-ethyl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; Zabedosertib [INN]; BAY-1834845; N1GRK350ZM; BAY1834845; BAY 1834845; 2-Pyridinecarboxamide, N-(6-(1-hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-; N-(6-(1-Hydroxy-1-methylethyl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)-2-pyridinecarboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methanesulfonyl)ethyl)- 2H-indazol-5-yl)-6-(trifluoromethyl)pyridine-2- carboxamide; N-(6-(2-Hydroxypropan-2-yl)-2-(2-(methylsulfonyl)ethyl)-2H-indazol-5-yl)-6-(trifluoromethyl)picolinamide; N-[6-(2-hydroxypropan-2-yl)-2-(2-methylsulfonylethyl)indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; UNII-N1GRK350ZM; SCHEMBL17785221; GTPL11415; OQAMEEFUUFJZRS-UHFFFAOYSA-N; BDBM395297; EX-A5143; US10308634, Example 12; MFCD32900903; AKOS040755617; SB74225; MS-28697; SY323200; HY-139374; CS-0198831; D96922; N-[6-(2-Hydroxy-2-propyl)-2-[2-(methylsulfonyl)ethyl]-2H-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide; N-{6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 2 [1]
Cross-matching ID
PubChem CID
121364961
TTD Drug ID
DMEZGWP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Renal carcinoma antigen NY-REN-64 (IRAK-4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-5718 DMRKU0L Rheumatoid arthritis FA20 Phase 2 [3]
CA-4948 DMWV8C6 Lymphoma 2A80-2A86 Phase 1 [4]
BAY1834845 DM8V62T Psoriasis vulgaris EA90 Phase 1 [5]
AZD6793 DM5GRZV Inflammation 1A00-CA43.1 Phase 1 [6]
SAR444656 DMIF2OL Atopic dermatitis EA80 Phase 1 [7]
Pyrazolopyrimidine and thienopyrimidine amide derivative 1 DM6TB4Z N. A. N. A. Patented [8]
Pyrazolopyrimidine and thienopyrimidine amide derivative 2 DMFUNH4 N. A. N. A. Patented [8]
Indazoletriazolephenyl derivative 1 DMHJDU6 N. A. N. A. Patented [8]
Indazoletriazolephenyl derivative 2 DMWZLK6 N. A. N. A. Patented [8]
Indazole amide derivative 2 DMRPT5O N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Renal carcinoma antigen NY-REN-64 (IRAK-4) TTKFVXR IRAK4_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT05656911) A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter Phase 2a Study to Investigate Efficacy and Safety of Zabedosertib (BAY 1834845) for the Treatment of Adult Patients With Moderate-to-severe Atopic Dermatitis. U.S.National Institutes of Health.
2 Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome. Biomed Pharmacother. 2022 Sep;153:113459.
3 IRAK4 degrader to take on innate immunity. Nat Biotechnol. 2020 Nov;38(11):1221-1223.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of AstraZeneca
7 Clinical pipeline report, company report or official report of Sanofi
8 Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).Expert Opin Ther Pat. 2016 Aug;26(8):917-32.